Amphastar Pharmaceuticals (AMPH) Stock Rating Lowered by BidaskClub
BidaskClub lowered shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from a strong-buy rating to a buy rating in a report issued on Thursday.
Several other brokerages have also recently weighed in on AMPH. ValuEngine raised Amphastar Pharmaceuticals from a hold rating to a buy rating in a research note on Friday, August 17th. Zacks Investment Research downgraded Amphastar Pharmaceuticals from a hold rating to a sell rating in a report on Friday, August 10th. Finally, Needham & Company LLC dropped their target price on Amphastar Pharmaceuticals from $24.00 to $22.00 and set a buy rating on the stock in a report on Friday, August 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $21.00.
Shares of AMPH stock opened at $18.48 on Thursday. The firm has a market capitalization of $855.28 million, a P/E ratio of 48.63, a PEG ratio of 8.43 and a beta of 1.42. Amphastar Pharmaceuticals has a twelve month low of $14.40 and a twelve month high of $20.45. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.24 and a current ratio of 1.94.
In other Amphastar Pharmaceuticals news, insider Jason B. Shandell sold 14,399 shares of the business’s stock in a transaction on Wednesday, July 11th. The stock was sold at an average price of $16.77, for a total value of $241,471.23. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO William J. Peters sold 2,407 shares of the business’s stock in a transaction on Thursday, August 16th. The stock was sold at an average price of $17.59, for a total value of $42,339.13. Following the completion of the sale, the chief financial officer now directly owns 86,836 shares in the company, valued at $1,527,445.24. The disclosure for this sale can be found here. Insiders sold 30,056 shares of company stock worth $515,505 over the last three months. Corporate insiders own 31.50% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the business. Wells Fargo & Company MN lifted its holdings in shares of Amphastar Pharmaceuticals by 9.1% during the first quarter. Wells Fargo & Company MN now owns 192,369 shares of the company’s stock valued at $3,606,000 after purchasing an additional 16,046 shares in the last quarter. Prudential Financial Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 8.4% during the first quarter. Prudential Financial Inc. now owns 62,380 shares of the company’s stock valued at $1,170,000 after purchasing an additional 4,850 shares in the last quarter. KBC Group NV lifted its holdings in shares of Amphastar Pharmaceuticals by 33.1% during the first quarter. KBC Group NV now owns 61,241 shares of the company’s stock valued at $1,148,000 after purchasing an additional 15,225 shares in the last quarter. Matarin Capital Management LLC bought a new position in shares of Amphastar Pharmaceuticals during the first quarter valued at $983,000. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Amphastar Pharmaceuticals by 3.3% during the first quarter. Dimensional Fund Advisors LP now owns 1,685,448 shares of the company’s stock valued at $31,602,000 after purchasing an additional 53,646 shares in the last quarter. 43.32% of the stock is currently owned by institutional investors and hedge funds.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.
Further Reading: How to Track your Portfolio in Google Finance
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.